The US Food and Drug Administration (FDA) today approved a new test to diagnose methicillin-resistant Staphylococcus aureus (MRSA), which will allow health workers to screen patients for MRSA colonization more quickly—in as little as 5 hours compared with 24 to 48 hours for traditional culture-based tests.
Rapid, biomarker-guided tests did not help cut antibiotic use in ICU patients.
Takeda's dengue vaccine candidate (TAK-003) is safe and effective against dengue virus, according to part 1 of phase 3 clinical trial results published yesterday in the New England Journal of Medicine.
Nonprofit drug developer TB Alliance announced today that it will partner with an Indian company to manufacture and commercialize pretomanid for treating extensively drug-resistant tuberculosis (XDR-TB).
An analysis of almost 160,000 pneumonia patients in 170 US hospitals indicates that urinary antigen testing (UAT), a practice recommended by national guidelines to allow for antibiotic de-escalation in patients with community-acquired pneumonia (CAP), is not widely performed, researchers reported today in Clinical Infectious Diseases.
Recognizing new research and more emphasis on antibiotic stewardship, experts say change was needed.
The drug, which was FDA-approved last month, went toe to toe with moxifloxacin.
In new polio developments, Pakistan reported five more wild poliovirus type 1 (WPV1) cases and four African countries reported more circulating vaccine-derived poliovirus type 2 (cVDPV2) cases, including the first in Benin, according to the latest weekly update today from the Global Polio Eradication Initiative (GPEI).
Fully 67.8% of patients received antibiotics for longer than recommended.
Viruses account for 61.4% of cases in young kids, with RSV the most common viral cause and the leading cause of severe pneumonia.
